in biotech Ecm -> how to end up at elite biotech buyside seat

To land an elite biotech buyside seat, here's a structured approach based on the most helpful WSO content:

1. Leverage Your ECM Experience

• ECM roles provide strong exposure to capital markets and biotech companies, but they lack the modeling and operational business understanding that buyside roles demand. To bridge this gap:
  • Focus on networking with biotech-focused IB groups or healthcare equity research (ER) teams. These groups are more aligned with the skill set required for buyside roles.
  • Develop a deep understanding of biotech investing. Start building a few strong biotech stock pitches to showcase your ability to evaluate companies.

2. Target Specific Groups

• Transitioning to a healthcare IB group (HC IB) or healthcare ER team is a strategic move. These groups are more likely to place candidates into biotech-focused buyside roles.
• If possible, aim for HC IB groups at top-tier banks with strong biotech deal flow. These groups often have better placement records into elite buyside seats.

3. Networking and Stock Pitches

• Use your biology background to your advantage by demonstrating a strong understanding of the science behind biotech companies. This can set you apart when networking with professionals in HC IB, ER, or buyside roles.
• Connect with people at funds, share your biotech stock pitches, and ask for feedback. This not only builds relationships but also shows your eagerness to learn and add value.

4. Consider the 2+2 Path

• The "2+2" path (2 years in IB/ER followed by 2 years in PE) is a common route to elite buyside roles. While ECM alone may not suffice, transitioning to HC IB or ER for 2 years can significantly strengthen your profile.
• After gaining HC IB/ER experience, recruit for a biotech-focused pod at a large multi-manager (MM) hedge fund or a mega-fund (MF) private equity firm.

5. Patience and Persistence

• Breaking into elite biotech buyside roles is highly competitive and often unstructured. Be prepared for a long-term effort, and remain persistent in networking and skill-building.

6. Key Takeaways

• Transition to HC IB or ER to develop the necessary skills and connections.
• Build and refine biotech stock pitches to demonstrate your investing acumen.
• Network aggressively with professionals in HC IB, ER, and buyside roles.
• Use your biology background to differentiate yourself in the recruiting process.

By targeting the right groups and strategically building your profile, you can position yourself for a successful transition to an elite biotech buyside seat.

Sources: Biotech finance: from IB to VC / HF to funded startup, Where does ER go from here?, https://www.wallstreetoasis.com/forum/private-equity/going-from-mm-investment-bank-to-mega-fund?customgpt=1, Going from IB to ECM or DCM? Anyone made this move?